ED50 and ED95 of remazolam for anesthesia induction during endoscopic submucosal dissection in elderly patients without sleep disorders: a modified sequential trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500110937

Enrollment

Unknown

Registered

2025-10-22

Start date

2025-11-01

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early gastric cancer

Interventions

Test group:The initial induction dose of remazolam was set at "0.2 mg/kg". The injection was administered within 30 seconds, followed by observation of the duration until the disappearance of the eyel

Eligibility

Sex/Gender

All

Age

65 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age 65-80 years; ASA grade I-III; body mass index (BMI) 18-30 kg/m^2; no preoperative sleep disorders.

Exclusion criteria

Exclusion criteria: Contraindications include: combination with other anesthesia methods; severe liver or kidney impairment; anemia or thrombocytopenia; serious heart, brain, lung, or kidney diseases; history of drug abuse and/or alcohol abuse; mental disorders that prevent participation in the trial; history of benzodiazepine allergy; and contraindicated for patients with myasthenia gravis, angle-closure glaucoma, severe depressive states, or schizophrenia.

Design outcomes

Primary

Measure	Time frame
ED50;ED95;	—

Countries

China

Contacts

Public ContactQi Shiyuan

Shanghai East Hospital

qishiyuan98@163.com+86 139 9806 1326

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026